drugset
drugset / Trial / NCT02231008

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

NCT02231008 ↗

Phase 2/3 Completed 49 enrolled Vanda Pharmaceuticals
RandomizedSingle-groupTriple-blindTreatment

Summary

The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.

Timeline

Start
2015-09
Primary completion
2018-11-19
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule — Oral

Indications

Smith-Magenis syndrome circadian rhythm sleep disorder